Q-omics provides the consensus-scored SUPT6H profile across patient tissues and cancer cell-line models. SUPT6H expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, SUPT6H is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, SUPT6H protein abundance shows 34,353 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BLCA, HNSC, and LSCC as cancer lineages where SUPT6H shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SUPT6H — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SUPT6H survival associations across molecular data types. SUPT6H RNA expression shows survival associations in the most cancer types (22), followed by mutation status (14) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SUPT6H RNA expression–survival associations across cancer types. High SUPT6H expression shows unfavorable associations in BLCA, ACC, LIHC, MESO and LGG, but favorable associations in KIRC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for SUPT6H RNA expression.
This table summarizes SUPT6H tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SUPT6H. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SUPT6H shows lower tumor expression in KICH and higher tumor expression in HNSC, LIHC, CHOL, COAD and STAD. The HNSC box plot shows higher SUPT6H RNA expression in tumor versus normal tissue (log2 FC = +0.754, t-test p < 0.001).
This table shows molecular features associated with SUPT6H in patient tissues and cancer cell lines. In patient samples, SUPT6H shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SUPT6H RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and UPPER_AERODIGESTIVE_TRACT.
